UY35664A - Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents

Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Info

Publication number
UY35664A
UY35664A UY0001035664A UY35664A UY35664A UY 35664 A UY35664 A UY 35664A UY 0001035664 A UY0001035664 A UY 0001035664A UY 35664 A UY35664 A UY 35664A UY 35664 A UY35664 A UY 35664A
Authority
UY
Uruguay
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
isoquinoline compounds
new isoindoline
Prior art date
Application number
UY0001035664A
Other languages
English (en)
Spanish (es)
Inventor
Imre Fejes
Guillouzic Anne-Françoise
Nyerges Miklos Lazlo
Tatai János
Paul Brough
Mark Dodsworth
Andras Kotschy
Meissner Johannes
Zoltan Szlavik
Chen I-Jen
Davidson James Edward Paul
De Nanteuil Guillaume
Olivier Geneste
Henlin Jean-Michel
Le Diguarher Thierry
Le Tiran Arnaud
Murray James Brooke
Starck Jérôme-Benoît
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of UY35664A publication Critical patent/UY35664A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
UY0001035664A 2013-07-23 2014-07-15 Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen UY35664A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1357276A FR3008977A1 (fr) 2013-07-23 2013-07-23 Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
UY35664A true UY35664A (es) 2015-01-30

Family

ID=49911606

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035664A UY35664A (es) 2013-07-23 2014-07-15 Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Country Status (49)

Country Link
US (3) US9809574B2 (enExample)
EP (1) EP3024826B1 (enExample)
JP (1) JP6395829B2 (enExample)
KR (1) KR102008431B1 (enExample)
CN (2) CN109456324B (enExample)
AP (1) AP2016008989A0 (enExample)
AR (1) AR097009A1 (enExample)
AU (1) AU2014295101B2 (enExample)
BR (1) BR112016001080B1 (enExample)
CA (1) CA2919572C (enExample)
CL (1) CL2016000148A1 (enExample)
CR (1) CR20160030A (enExample)
CU (1) CU24352B1 (enExample)
CY (1) CY1121247T1 (enExample)
DK (1) DK3024826T3 (enExample)
DO (1) DOP2016000009A (enExample)
EA (1) EA032301B1 (enExample)
ES (1) ES2711371T3 (enExample)
FR (1) FR3008977A1 (enExample)
GE (1) GEP20207070B (enExample)
HK (1) HK1218754A1 (enExample)
HR (1) HRP20190277T1 (enExample)
HU (1) HUE041443T2 (enExample)
IL (1) IL243449A0 (enExample)
JO (1) JO3457B1 (enExample)
LT (1) LT3024826T (enExample)
MA (1) MA38801B1 (enExample)
MD (1) MD4793C1 (enExample)
ME (1) ME03346B (enExample)
MX (1) MX365373B (enExample)
MY (1) MY193619A (enExample)
NI (1) NI201600016A (enExample)
NZ (1) NZ716155A (enExample)
PE (1) PE20160241A1 (enExample)
PH (1) PH12016500034A1 (enExample)
PL (1) PL3024826T3 (enExample)
PT (1) PT3024826T (enExample)
RS (1) RS58344B1 (enExample)
RU (1) RU2689305C2 (enExample)
SA (1) SA516370439B1 (enExample)
SG (1) SG11201600205XA (enExample)
SI (1) SI3024826T1 (enExample)
TN (1) TN2016000003A1 (enExample)
TR (1) TR201819155T4 (enExample)
TW (1) TWI560184B (enExample)
UA (1) UA117490C2 (enExample)
UY (1) UY35664A (enExample)
WO (1) WO2015011164A1 (enExample)
ZA (1) ZA201600198B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112018071548A2 (pt) 2016-04-20 2019-04-16 Bristol-Myers Squibb Company compostos heterocíclicos bicíclicos substituídos
SG11202013026WA (en) 2018-06-27 2021-01-28 Proteostasis Therapeutics Inc Proteasome activity enhancing compounds
EP4059928A4 (en) * 2019-11-15 2023-11-15 Wuhan LL Science and Technology Development Co., Ltd. Rock inhibitor, preparation method therefor and use thereof
CN112010796B (zh) * 2020-09-17 2022-04-22 浙江大学 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system
AR125205A1 (es) * 2021-03-24 2023-06-21 Servier Lab Nuevo proceso para la síntesis de derivados del ácido 5-{5-cloro-2-[(3s)-3-[(morfolin-4-il)metil]-3,4-dihidroisoquinolina-2(1h)-carbonil]fenil}-1,2-dimetil-1h-pirrol-3-carboxílico y su aplicación para la producción de compuestos farmacéuticos
CN119053587A (zh) 2022-02-24 2024-11-29 法国施维雅药厂 5-[7-(3,4-二氢-1h-异喹啉-2-羰基)-1,2,3,4四氢异喹啉-6-基]-1h-吡咯-3-甲酰胺衍生物、含有其的药物组合物及其作为促细胞凋亡剂的用途
PE20251072A1 (es) 2022-05-20 2025-04-10 Novartis Ag Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos
CN121001985A (zh) * 2023-03-31 2025-11-21 三井化学株式会社 氨基甲酸酯化合物
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093297A2 (en) 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
WO2004096774A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
CN101039662A (zh) * 2004-08-20 2007-09-19 密执安州立大学董事会 抗-细胞凋亡bcl-2家族成员的小分子抑制剂及其应用
US8557812B2 (en) * 2004-08-20 2013-10-15 The Regents Of The University Of Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US20080227792A1 (en) * 2005-02-15 2008-09-18 Novo Nordisk A/S 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters
EP3243814B1 (en) 2007-04-16 2018-10-17 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
CN102007101A (zh) 2007-11-30 2011-04-06 生物区科学管理控股有限公司 作为抗菌剂的四氢-异喹啉ppat抑制剂
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
WO2009102463A2 (en) 2008-02-14 2009-08-20 Connor Reynolds Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same
WO2012162365A1 (en) * 2011-05-25 2012-11-29 Bristol-Myers Squibb Company Substituted sulfonamides useful as antiapoptotic bcl inhibitors
EP2794591A1 (en) * 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
EP2798432A4 (en) 2011-12-27 2015-07-22 Intel Corp METHODS AND SYSTEMS FOR CONTROLLING POWER SUPPLY NETWORKS DURING AN ACTIVE STATE OF A PERIODICALLY TRIGGERED DOMAIN IN ACCORDANCE WITH PERIODICALLY RELEASED DOMAIN LOADING CONDITIONS
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008977A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP2016525529A (ja) 2016-08-25
PL3024826T3 (pl) 2019-05-31
MX2016000904A (es) 2016-04-25
MY193619A (en) 2022-10-20
CA2919572A1 (en) 2015-01-29
ZA201600198B (en) 2019-07-31
CN109456324B (zh) 2022-04-22
MD4793B1 (ro) 2022-02-28
JO3457B1 (ar) 2020-07-05
PH12016500034B1 (en) 2016-03-28
TWI560184B (en) 2016-12-01
DOP2016000009A (es) 2016-03-15
DK3024826T3 (en) 2019-03-04
PH12016500034A1 (en) 2016-03-28
MD4793C1 (ro) 2022-09-30
US20180002313A1 (en) 2018-01-04
MX365373B (es) 2019-05-31
MA38801A1 (fr) 2018-05-31
CA2919572C (en) 2017-06-20
EA032301B1 (ru) 2019-05-31
CN105431422A (zh) 2016-03-23
CN105431422B (zh) 2019-08-30
UA117490C2 (uk) 2018-08-10
BR112016001080B1 (pt) 2022-04-05
HUE041443T2 (hu) 2019-05-28
IL243449A0 (en) 2016-02-29
RU2689305C2 (ru) 2019-05-27
CU20160010A7 (es) 2016-06-29
US10689364B2 (en) 2020-06-23
RU2016106003A (ru) 2017-08-28
TW201504228A (zh) 2015-02-01
CR20160030A (es) 2016-03-09
AP2016008989A0 (en) 2016-01-31
HK1218754A1 (zh) 2017-03-10
EA201600122A1 (ru) 2016-07-29
HRP20190277T1 (hr) 2019-04-05
EP3024826A1 (en) 2016-06-01
JP6395829B2 (ja) 2018-09-26
EP3024826B1 (en) 2018-11-14
TR201819155T4 (tr) 2019-01-21
ES2711371T3 (es) 2019-05-03
CU24352B1 (es) 2018-07-05
CY1121247T1 (el) 2020-05-29
TN2016000003A1 (en) 2017-07-05
FR3008977A1 (fr) 2015-01-30
AU2014295101B2 (en) 2018-05-31
RS58344B1 (sr) 2019-03-29
MA38801B1 (fr) 2019-03-29
ME03346B (me) 2019-10-20
AU2014295101A1 (en) 2016-02-04
CN109456324A (zh) 2019-03-12
CL2016000148A1 (es) 2016-08-12
NI201600016A (es) 2016-02-11
NZ716155A (en) 2019-05-31
GEP20207070B (en) 2020-02-25
BR112016001080A2 (enExample) 2017-07-25
SI3024826T1 (sl) 2019-03-29
MD20160018A2 (ro) 2016-07-31
SG11201600205XA (en) 2016-02-26
HK1222856A1 (en) 2017-07-14
US9809574B2 (en) 2017-11-07
LT3024826T (lt) 2019-02-25
KR102008431B1 (ko) 2019-08-07
KR20160033224A (ko) 2016-03-25
AR097009A1 (es) 2016-02-10
US11028070B2 (en) 2021-06-08
SA516370439B1 (ar) 2019-06-27
US20200262816A1 (en) 2020-08-20
US20160194304A1 (en) 2016-07-07
WO2015011164A1 (en) 2015-01-29
PE20160241A1 (es) 2016-04-30
PT3024826T (pt) 2019-01-28

Similar Documents

Publication Publication Date Title
UY35664A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2017005587A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2017005589A (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2014000282A (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que lo contienen
SV2014004771A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
NI201600015A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY35653A (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2014004879A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230525